HEOR & Access Manager at Eli Lilly and Company

Bogotá, Bogota, Colombia

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

Bachelor’s degree in Economics, Public Health, or related field
Master’s or PhD in Health Economics, Epidemiology, or Outcomes Research
Minimum 5 years of experience in HEOR and market access within oncology, rare diseases, or specialty care products in a commercial environment
Proven experience with economic modeling, RWE generation, and HTA submissions in Colombia
Strong knowledge of the Colombian healthcare system, payer landscape, and regulatory environment
Proven experience participating in international HEOR or access working groups or conferences
Proven experience submitting HEOR manuscripts in scientific journals, as well as posters or oral presentations in high-impact local or international meetings
Proven experience working with conventional but also disruptive HEOR & Access vendors
Excellent communication and stakeholder engagement skills
Willingness to 20% travel or working elsewhere on Access field activities
Fluent in English and Spanish

Responsibilities

Design and implement HEOR strategies to support product value propositions throughout the lifecycle, from early development to post-launch (aligned to local payer requirements)
Work closely with Pricing and Reimbursement (and also with Medical, Legal and Finance Teams) in design and reach internal approval for innovative negotiation models; and work closely with Access on Field Team to implement those models
Work closely with Business Intelligence & Access (BI & PRA) in performing predictive models, to demonstrate the clinical and financial impact of innovative negotiations on health contracting models between HMOs and HCOs
Work closely with Real-World Evidence (RWE) generating and synthesizing evidence to support reimbursement submissions and access negotiations
Lead the development of local value dossiers for HMOs, MOH and health technology assessment dossiers for HTA agency
Collaborate cross-functionally with local Medical Affairs, Regulatory, Commercial, Access on field Teams, and Global functions in general
Work closely with Corporate Affairs engaging external stakeholders including MOH, payers, HTA bodies, academic institutions, and patient advocacy groups
Co-create support materials for communication with payers alongside marketing and medical teams
Present value proposals to payers and other relevant stakeholders in the access strategy
Monitor healthcare policy trends and access barriers in Colombia and the region to inform strategic planning
Lead internal field teams training and communication on HEOR & Access topics

Skills

HEOR

Health Economics

Outcomes Research

Pricing and Reimbursement

Value Dossiers

Real-World Evidence

RWE

Health Technology Assessment

HTA

Predictive Modeling

Access Strategy

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free